Mark Leeds, D.O.
Mark Leeds, D.O.
Ozempic for Alcoholism: Could GLP-1 Peptides Help to Treat Alcohol Use Disorder?
Ozempic for Alcoholism: Could GLP-1 Peptides Help to Treat Alcohol Use Disorder?
Ozempic for Alcoholism: Could GLP-1 Peptides Help to Treat Alcohol Use Disorder?
Saturday 5th October 2024
Explore how GLP-1 receptor agonists like Ozempic could revolutionise alcohol addiction treatment in this insightful episode with Dr. Mark Leeds.
8 minutes
Inspiring
Informative
Hopeful
Compassionate
Encouraging
About this podcast
Author:
Mark Leeds, D.O.
Overview:
Categories:
Innovative Treatments & Recovery Paths
Sobriety Toolkit
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
381 (View all)
Do you want to link to this podcast?
Get the buttons here!Can Weight-Loss Drugs Help Treat Alcoholism? Exploring GLP-1 Peptides
Episode Overview
- GLP-1 drugs like Ozempic may reduce alcohol cravings.
- Patients report decreased interest in alcohol while on these medications.
- Livengrin Foundation is researching the use of GLP-1 drugs in addiction treatment.
- Holistic approaches consider both physical and mental aspects of addiction.
- Clinical trials are underway to explore long-term effectiveness.
Within weeks of starting the medication, Zuri noticed a significant change in her relationship with alcohol.
Could a weight-loss drug help treat alcohol addiction? In this episode, Dr. Mark Leeds dives into the surprising potential of GLP-1 receptor agonists like Ozempic for treating Alcohol Use Disorder (AUD). Meet Zuri, a 42-year-old marketing executive who struggled with alcohol dependency for over a decade. Traditional treatments didn't work for her, but an unexpected recommendation from her doctor changed everything.
Within weeks of starting a GLP-1 medication, Zuri noticed a significant drop in her urge to drink, marking a dramatic shift in her recovery journey. The episode sheds light on the science behind this breakthrough. GLP-1 drugs, initially developed for diabetes and weight loss, are now being explored for their effects on the brain's reward system. Researchers believe these medications could reduce cravings for both food and alcohol, offering a dual benefit that's catching the attention of addiction specialists.
Philadelphia's Livengrin Foundation is at the forefront of this research, exploring how these drugs can be integrated into comprehensive addiction treatment plans. Their holistic approach considers both physical and mental aspects of addiction, aiming to improve overall patient outcomes. The foundation's medical director emphasizes the importance of setting target weights and maintaining proper nutrition while on the medication. The potential impact of GLP-1 drugs on addiction recovery is generating excitement in the medical community.
Patients report not only a reduced desire for alcohol but also altered taste perceptions, making alcohol less appealing. This change in behaviour could lead to naturally decreased alcohol consumption without conscious effort. As more data emerges, the future of addiction treatment looks promising. Clinical trials are underway to further explore the effectiveness of GLP-1 drugs. If successful, these medications could become a valuable tool in the fight against alcoholism and possibly other forms of addiction.
Curious about how a weight-loss drug could change the game for addiction treatment? Tune in to hear more about this fascinating development and what it could mean for those struggling with alcohol dependency.